Mesoblast Limited hosted a webinar featuring Dr. Susan Prockop discussing Ryoncil (remestemcel-L-rknd) as a new treatment approach for pediatric acute graft-versus-host disease (aGvHD), used after steroids. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory aGvHD in children, showing promise in pivotal trials and case studies. Mesoblast is also developing Ryoncil for other inflammatory diseases and expanding its cell therapy portfolio globally. This highlights advancing treatment options for severe inflammatory conditions in pediatric patients.
Mesoblast Limited (MESO) shares are trading at USD 14.79 as of Nov 05, 2026 07:31 WIB on Pluang, showing a modest 0.14% increase in one day. This price sits closer to its 52-week low of USD 11.95 than its high of USD 20.96, indicating the stock remains below its peak despite recent positive developments. Investors typically hold MESO shares for about 16 days on the platform.
